iiinova — where your digital self keeps evolving

MyOme

@myome.com

We help families understand their DNA, and how it impacts their health throughout their lives, with secure and portable data using the latest technologies.

Posts Replies Media

MyOme @myome.com · 21/05/2026

Akash Kumar joins the @globalgenes.bsky.social RARECast podcast to explain how genome sequencing is becoming increasingly integrated into clinical care pathways, particularly for patients with suspected rare diseases: globalgenes.org/raredaily/cu... #RARECast

000

Reposted by MyOme

ACMG @theacmg.bsky.social · 27/01/2026

Save the date! #MedicalGeneticsAwareness Week returns March 10–14 with the theme “Making a Difference Together.” Help spotlight the impact of #medicalgenetics professionals with your social media posts or videos. Sponsored by @myome.com. Resources: tinyurl.com/5drf4pep

011

MyOme @myome.com · 24/02/2026

At MyOme, we’ve disrupted the serial testing paradigm. By using a comprehensive whole-genome backbone for every test, we see what traditional methods miss—from difficult-to-resolve tandem repeats to mitochondrial DNA variants. See the difference a genome-first approach makes. youtu.be/SaOs7E0GqeQ

youtu.be

MyOme Rare Disease Diagnostic Testing

YouTube video by MyOme

000

MyOme @myome.com · 12/03/2025

Join us at #ACMG2025 We will be showcasing our upcoming rare disease products in our showcase, Advancing Rare Disease Diagnostics, on March 19th at 12:15 PM PST. Lunch will be provided. Register here: lnkd.in/gP847QVR

001

Reposted by MyOme

DNAnexus, Inc. @dnanexus.bsky.social · 25/02/2025

Our next roundtable covers the challenges & strategies for integrating vast, multi-modal datasets into their clinical testing workflows. hello.dnanexus.com/webinar/inno... @dcgenomics.bsky.social @labcorp.bsky.social @premalshah.bsky.social h.bsky.social @myome.com

Live webinar: Innovations in Clinical Testing for Oncology & Rare Diseases. Taking place on march 6th at 11am ET.

022

MyOme @myome.com · 27/02/2025

Today we are excited to launch CAD iPRS — a cutting-edge, genome-wide polygenic risk score for coronary artery disease. Empowering primary care to identify high-risk patients and personalize prevention strategies. Read more here: prnewswire.com/news-release...

000

MyOme @myome.com · 19/02/2025

MyOme’s Dr. Akash Kumar will speak at WashU Medicine’s Rare Disease Day event on: 📅 Feb 20 | 1:45PM PT / 3:45PM CT 🧬 Shortening Diagnostic Timelines for Rare Diseases – A Whole-Genome Platform Approach

000

Reposted by MyOme

DNAnexus, Inc. @dnanexus.bsky.social · 13/02/2025

Join our discussion on clinical testing innovations that are enabling organizations to derive insights into #oncology & #raredisease. hello.dnanexus.com/webinar/inno... @dcgenomics.bsky.social @labcorp.bsky.social @premalshah.bsky.social @myome.com

hello.dnanexus.com

Innovations in Clinical Testing for Oncology & Rare Diseases

Clinical testing for oncology and rare diseases faces unique challenges that demand innovative solutions. Patient recruitment and retention remain significant hurdles, with stringent eligibility crite...

021

MyOme @myome.com · 30/01/2025

We're partnering with Novi Health to bring whole genome testing to employer health programs. Through this collaboration, employees and their families gain access to whole genome sequencing, integrated risk (with PRS) reports, and expert genetic counseling. prn.to/4jzWF7T

prnewswire.com

MyOme and Novi Health Collaborate to Bring Whole Genome Testing to Employer Health Programs

/PRNewswire/ -- MyOme, a leading clinical innovation whole genomic analysis and polygenic risk modelling (PRS) company announced a strategic partnership with...

011

MyOme @myome.com · 14/01/2025

MyOme's CEO, Premal S. Shah, PhD, is excited to speak at #PMWC2025 on Feb 6 at 2 PM. We'll discuss integrated polygenic risk scores for breast cancer & coronary artery disease. Learn more: pmwcintl.com/program/ #PrecisionMedicine

010

MyOme @myome.com · 09/12/2024

Big news! 🧬 Natera & MyOme launch iPRS™, a personalized tool to assess breast cancer risk. Backed by research, iPRS integrates >1M genetic markers & clinical inputs for accurate, cross-ancestry insights. Learn more: ow.ly/mGsJ50UntLt #BreastCancer #Genetics

ow.ly

Natera and MyOme Announce Launch of iPRS™ for Breast Cancer Risk Assessment

Cross-ancestry polygenic risk score now offered with the Empower™ hereditary cancer test AUSTIN, Texas–(BUSINESS WIRE)– Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testin...

051